PacBio Announces Third Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Pacific Biosciences of California (PACB) PT Raised to $32 at Cowen
November 3, 2021 6:30 AM EDTCowen analyst Dan Brennan raised the price target on Pacific Biosciences of California (NASDAQ: PACB) to $32.00 (from $30.00) while maintaining a Market Perform rating.
The analyst commented, "PACB reported a good 3Q, with revenues +83% Y/Y, ~5% ahead of expectations, and service, consumables, & instrument revenues... More
